Results 21 to 30 of about 2,780 (190)

CIP2A Inhibits PP2A in Human Malignancies [PDF]

Cell, 2007
Inhibition of protein phosphatase 2A (PP2A) activity has been identified as a prerequisite for the transformation of human cells. However, the molecular mechanisms by which PP2A activity is inhibited in human cancers are currently unclear. In this study, we describe a cellular inhibitor of PP2A with oncogenic activity. The protein, designated Cancerous
Centre for Biotechnology, University of Turku and Åbo Akademi University Turku, Finland ( host institution ), Junttila, Melissa R. ( author ), Puustinen, Pietri ( author ), Niemelä, Minna ( author ), Ahola, Raija ( author ), Arnold, Hugh ( author ), Böttzauw, Trine ( author ), Ala-aho, Risto ( author ), Nielsen, Christina ( author ), Ivaska, Johanna ( author ), Taya, Yoichi ( author ), Lu, Shi-Long ( author ), Lin, Shujun ( author ), Chan, Edward K.L. ( author ), Wang, Xiao-Jing ( author ), Grènman, Reidar ( author ), Kast, Juergen ( author ), Kallunki, Tuula ( author ), Sears, Rosalie ( author ), Kähäri, Veli-Matti ( author ), Westermarck, Jukka ( author )   +20 more
openaire   +5 more sources

CIP2A Is Associated with Human Breast Cancer Aggressivity [PDF]

Clinical Cancer Research, 2009
Abstract Purpose: To investigate the clinical relevance of the recently characterized human oncoprotein cancerous inhibitor of protein phosphatase 2A (CIP2A) in human breast cancer. Experimental Design: CIP2A expression (mRNA and protein) was measured in three different sets of human mammary tumors and compared with ...
Côme, Christophe, Laine, Anni, Chanrion, Maïa, Edgren, Henrik, Mattila, Elina, Lin, Xiaoling, Jonkers, Jos, Ivaska, Johanna, Isola, Jorma, Darbon, Jean-Marie, Kallioniemi, Olli, Thézenas, Simon, Westermarck, Jukka   +12 more
openaire   +3 more sources

CIP2A influences survival in colon cancer and is critical for maintaining Myc expression. [PDF]

PLoS ONE, 2013
The cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncogenic factor that stabilises the c-Myc protein. CIP2A is overexpressed in several tumours, and expression levels are an independent marker for long-term outcome.
Armin Wiegering, Christina Pfann, Friedrich Wilhelm Uthe, Christoph Otto, Lukas Rycak, Uwe Mäder, Martin Gasser, Anna-Maria Waaga-Gasser, Martin Eilers, Christoph-Thomas Germer   +9 more
doaj   +1 more source

siRNA-Mediated Silencing of CIP2A Enhances Docetaxel Activity Against PC-3 Prostate Cancer Cells [PDF]

Advanced Pharmaceutical Bulletin, 2017
Purpose: Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an identified human oncoprotein which modulates malignant cell growth. It is overexpressed in human prostate cancer and in most of the human malignancies.
Saiedeh Razi Soofiyani, Akbar Mohammad Hoseini, Ali Mohammadi, Vahid Khaze Shahgoli, Behzad Baradaran, Mohammad Saeid Hejazi   +5 more
doaj   +1 more source

From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer

Frontiers in Genetics, 2023
Cancerous inhibitor of protein phosphatase 2A (CIP2A), initially reported as a tumor-associated antigen (known as p90), is highly expressed in most solid and hematological tumors. The interaction of CIP2A/p90, protein phosphatase 2A (PP2A), and c-Myc can
Beibei Chen, Beibei Chen, Huihui Hu, Huihui Hu, Xiaobing Chen, Xiaobing Chen   +5 more
doaj   +1 more source

Relationship Between CIP2A and Endometrium Cancer

Journal of the College of Physicians and Surgeons Pakistan, 2020
To determine whether there is a relationship between endometrium cancer and the oncoprotein cancerous inhibitor of protein phosphatase 2A (CIP2A).A descriptive study.Balıkesir University Medical Faculty Hospital, Balıkesir, Turkey, from January 2013 to July 2018.CIP2A was studied immunohistochemically and molecularly in paraffin blocks. The correlation
Aslan, Figen, Güney, Gürhan, Avcıkurt, Ayla Solmaz, Taşkın, Mine İslimye, Akgün, Gizem Akkaş   +4 more
openaire   +4 more sources

CIP2A Promotes T-Cell Activation and Immune Response to Listeria monocytogenes Infection. [PDF]

PLoS ONE, 2016
The oncoprotein Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) is overexpressed in most malignancies and is an obvious candidate target protein for future cancer therapies. However, the physiological importance of CIP2A-mediated PP2A inhibition is
Christophe Côme, Anna Cvrljevic, Mohd Moin Khan, Irina Treise, Thure Adler, Juan Antonio Aguilar-Pimentel, Byron Au-Yeung, Eleonora Sittig, Teemu Daniel Laajala, Yiling Chen, Sebastian Oeder, Julia Calzada-Wack, Marion Horsch, Tero Aittokallio, Dirk H Busch, Markus W Ollert, Frauke Neff, Johannes Beckers, Valerie Gailus-Durner, Helmut Fuchs, Martin Hrabě de Angelis, Zhi Chen, Riitta Lahesmaa, Jukka Westermarck   +23 more
doaj   +1 more source

CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes [PDF]

Oncogene, 2012
Protein phosphatase 2A (PP2A) is a critical human tumor-suppressor complex. A recently characterized PP2A inhibitor protein, namely cancerous inhibitor of PP2A (CIP2A), has been found to be overexpressed at a high frequency in most of the human cancer types.
Westermarck Jukka, Nicorici D., Joensuu H., Sihto H., Mpindi J-P, Kallioniemi O-P, Hautaniemi S., Tuntematon , Nicorici D., Joensuu H., Sihto H., Mpindi J-P, Kallioniemi O-P, Hautaniemi S.   +13 more
openaire   +4 more sources

CIP2A mediates fibronectin-induced bladder cancer cell proliferation by stabilizing β-catenin

Journal of Experimental & Clinical Cancer Research, 2017
Background Fibronectin (FN) is associated with tumorigenesis and progression in bladder cancer, however, the underlying mechanisms causing this remain largely unknown.
Fengbin Gao, Tianyuan Xu, Xianjin Wang, Shan Zhong, Shanwen Chen, Minguang Zhang, Xiaohua Zhang, Yifan Shen, Xiaojing Wang, Chen Xu, Zhoujun Shen   +10 more
doaj   +1 more source

High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia. [PDF]

, 2016
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a predictive biomarker of disease progression in many malignancies, including imatinib-treated chronic myeloid leukemia (CML).
Butterworth, M., Carmell, N., Clark, R.E., Cohen, G.M., Lucas, C.M., Milani, M., Scott, L.J., Varadarajan, S.   +7 more
core   +1 more source